Response to "Variability of cognitive changes after donanemab treatment".
作者信息
Daly Timothy, Kepp Kasper P, Imbimbo Bruno P
机构信息
UMR 1219 Bordeaux Population Health, Université de Bordeaux & INSERM, Bordeaux, France.
Bioethics Program, FLACSO Argentina, Buenos Aires, Argentina.
出版信息
Alzheimers Dement. 2025 Feb;21(2):e14520. doi: 10.1002/alz.14520. Epub 2025 Jan 8.
Abstract
摘要
相似文献
1
Response to "Variability of cognitive changes after donanemab treatment".对“多奈单抗治疗后认知变化的变异性”的回应
Alzheimers Dement. 2025 Feb;21(2):e14520. doi: 10.1002/alz.14520. Epub 2025 Jan 8.
2
Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.在轻度认知障碍和阿尔茨海默病患者中，比较 donanemab、lecanemab、aducanumab 和锂对认知功能的疗效、耐受性和可接受性：一项系统评价和网络荟萃分析。
Ageing Res Rev. 2024 Feb;94:102203. doi: 10.1016/j.arr.2024.102203. Epub 2024 Jan 20.
3
Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.多奈单抗、莱卡奈单抗、阿杜卡单抗、褪黑素及有氧运动对轻度认知障碍和轻度阿尔茨海默病认知功能短期影响的疗效、耐受性及可接受性比较：一项系统评价与网状Meta分析
J Alzheimers Dis. 2024;98(3):825-835. doi: 10.3233/JAD-230911.
4
Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.Donanemab（LY3002813）在阿尔茨海默病中的 1b 期研究：用 Florbetapir F18 成像测量脑淀粉样蛋白的快速和持续减少。
J Prev Alzheimers Dis. 2021;8(4):414-424. doi: 10.14283/jpad.2021.56.
5
Targeting Amyloid Pathology in Early Alzheimer's: The Promise of Donanemab-Azbt.针对早期阿尔茨海默病中的淀粉样蛋白病理：多奈单抗-阿兹特的前景
Pharmacy (Basel). 2025 Feb 8;13(1):23. doi: 10.3390/pharmacy13010023.
6
Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's.对治疗阿尔茨海默病的多那单抗的药代动力学评估。
Expert Opin Drug Metab Toxicol. 2024 Jun;20(6):411-417. doi: 10.1080/17425255.2024.2357637. Epub 2024 May 20.
7
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.多纳单抗（LY3002813）在阿尔茨海默病中的剂量递增研究。
Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12112. doi: 10.1002/trc2.12112. eCollection 2021.
8
Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials.多奈单抗治疗阿尔茨海默病：临床试验的系统评价
Healthcare (Basel). 2022 Dec 22;11(1):32. doi: 10.3390/healthcare11010032.
9
How donanemab data address the coverage with evidence development questions.度拉糖肽数据如何解决有证据开发问题的覆盖范围。
Alzheimers Dement. 2024 Apr;20(4):3127-3140. doi: 10.1002/alz.13700. Epub 2024 Feb 7.
10
Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.Donanemab 的群体药代动力学、阿尔茨海默病患者的淀粉样斑块减少和安全性。
Clin Pharmacol Ther. 2023 Jun;113(6):1258-1267. doi: 10.1002/cpt.2875. Epub 2023 Mar 9.
本文引用的文献
1
Variability of cognitive changes after donanemab treatment.多奈单抗治疗后认知变化的变异性。
Alzheimers Dement. 2025 Jan;21(1):e14576. doi: 10.1002/alz.14576.
2
Are lecanemab and donanemab disease-modifying therapies?lecanemab和donanemab是改变疾病进程的疗法吗？
Alzheimers Dement. 2024 Sep;20(9):6659-6661. doi: 10.1002/alz.14114. Epub 2024 Aug 3.
3
Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42.重新校准 Lecanemab 和 Donanemab 的风险效益比：量表、免疫反应性和淀粉样蛋白-β42 的变化。
J Alzheimers Dis. 2024;99(3):877-881. doi: 10.3233/JAD-240171.
4
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
5
Alzheimer's disease: Lecanemab gets full FDA approval and black box safety warning.阿尔茨海默病：仑卡奈单抗获得美国食品药品监督管理局全面批准并附有黑框安全警告。
BMJ. 2023 Jul 7;382:1580. doi: 10.1136/bmj.p1580.
6
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
Zotero 插件